SNYNF Quote, Financials, Valuation and Earnings

AstraZeneca PLC has a net margin of 17.65% compared to Sanofi SA's net margin of 21.46%. Sanofi SA's return on equity of 8.47% beat AstraZeneca PLC's return on equity of 19.55%.

Sanofi SA has a consensus price target of --, signalling upside risk potential of 21.6%. On the other hand AstraZeneca PLC has an analysts' consensus of $84.60 which suggests that it could grow by 20.15%. Given that Sanofi SA has higher upside potential than AstraZeneca PLC, analysts believe Sanofi SA is more attractive than AstraZeneca PLC.

Sanofi SA has a beta of 0.367, which suggesting that the stock is 63.329% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.396, suggesting its less volatile than the S&P 500 by 60.428%.

Sanofi SA has a quarterly dividend of $4.40 per share corresponding to a yield of 4.18%. AstraZeneca PLC offers a yield of 2.2% to investors and pays a quarterly dividend of $1.05 per share. Sanofi SA pays 84.6% of its earnings as a dividend. AstraZeneca PLC pays out 65.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are smaller than AstraZeneca PLC quarterly revenues of $13.6B. Sanofi SA's net income of $2B is lower than AstraZeneca PLC's net income of $2.9B. Notably, Sanofi SA's price-to-earnings ratio is 18.80x while AstraZeneca PLC's PE ratio is 28.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.71x versus 4.00x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 17.65% compared to Sanofi SA's net margin of -907.48%. Sanofi SA's return on equity of 8.47% beat Moderna's return on equity of -29.23%.

Sanofi SA has a consensus price target of --, signalling upside risk potential of 21.6%. On the other hand Moderna has an analysts' consensus of $47.70 which suggests that it could grow by 81.63%. Given that Moderna has higher upside potential than Sanofi SA, analysts believe Moderna is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.367, which suggesting that the stock is 63.329% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Sanofi SA has a quarterly dividend of $4.40 per share corresponding to a yield of 4.18%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sanofi SA quarterly revenues are $11.2B, which are larger than Moderna quarterly revenues of $107M. Sanofi SA's net income of $2B is higher than Moderna's net income of -$971M. Notably, Sanofi SA's price-to-earnings ratio is 18.80x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.71x versus 3.25x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of 17.65% compared to Sanofi SA's net margin of 21.63%. Sanofi SA's return on equity of 8.47% beat Pfizer's return on equity of 8.72%.

Sanofi SA has a consensus price target of --, signalling upside risk potential of 21.6%. On the other hand Pfizer has an analysts' consensus of $29.50 which suggests that it could grow by 26.5%. Given that Pfizer has higher upside potential than Sanofi SA, analysts believe Pfizer is more attractive than Sanofi SA.

Sanofi SA has a beta of 0.367, which suggesting that the stock is 63.329% less volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Sanofi SA has a quarterly dividend of $4.40 per share corresponding to a yield of 4.18%. Pfizer offers a yield of 7.29% to investors and pays a quarterly dividend of $0.43 per share. Sanofi SA pays 84.6% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Sanofi SA quarterly revenues are $11.2B, which are smaller than Pfizer quarterly revenues of $13.7B. Sanofi SA's net income of $2B is lower than Pfizer's net income of $3B. Notably, Sanofi SA's price-to-earnings ratio is 18.80x while Pfizer's PE ratio is 16.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanofi SA is 2.71x versus 2.13x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.